Rao Amanda, Ebelt Phillippa, Mallard Alistair, Briskey David
RDC Clinical, Brisbane, 4006 Australia.
University of Sydney, School of Medicine, Sydney, Australia.
Sleep Sci Pract. 2021;5(1):12. doi: 10.1186/s41606-021-00065-3. Epub 2021 Sep 10.
Sleep is essential for wellbeing, yet sleep disturbance is a common problem linked to a wide range of health conditions. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide proposed to promote better sleep via potential interaction with the endocannabinoid system.
This double-blind, randomised study on 103 adults compared the efficacy and tolerability of 8 weeks of daily supplemented PEA formulation (350 mg Levagen + ®) to a placebo. Sleep quality and quantity were measured using wrist actigraphy, a sleep diary and questionnaires.
At week 8, PEA supplementation reduced sleep onset latency, time to feel completely awake and improved cognition on waking. After 8 weeks, both groups improved their sleep quality and quantity scores similarly. There was no difference between groups at baseline or week 8 for sleep quantity or quality as measured from actigraphy or sleep diaries.
These findings support PEA as a potential sleeping aid capable of reducing sleep onset time and improving cognition on waking.
Australian New Zealand Clinical Trials Registry ACTRN12618001339246. Registered 9 August 2018.
睡眠对健康至关重要，但睡眠障碍是一个与多种健康状况相关的常见问题。棕榈酰乙醇胺（PEA）是一种内源性脂肪酸酰胺，通过与内源性大麻素系统的潜在相互作用，有望改善睡眠。
这项针对103名成年人的双盲随机研究，比较了每日补充8周PEA制剂（350毫克Levagen + ®）与安慰剂的疗效和耐受性。使用手腕活动记录仪、睡眠日记和问卷来测量睡眠质量和睡眠时间。
在第8周时，补充PEA可缩短入睡潜伏期、完全清醒所需时间，并改善醒来时的认知能力。8周后，两组的睡眠质量和睡眠时间得分改善程度相似。从活动记录仪或睡眠日记测量的睡眠量或质量来看，两组在基线或第8周时没有差异。
这些发现支持PEA作为一种潜在的睡眠辅助剂，能够缩短入睡时间并改善醒来时的认知能力。
澳大利亚新西兰临床试验注册中心ACTRN12618001339246。于2018年8月9日注册。
